Press Releases Sun Pharmaceutical Industries Ltd.

Stocks

SUNPHARMA

INE044A01036

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 04:35:09 12/06/2026 pm IST			5-day change	1st Jan Change
1,807.70 ^INR	+0.75%		+1.43%	+5.12%

10/06	Organon wins US approval to widen use of arthritis biosimilar drug	RE
09/06	Organon Acquisition May Receive $1 Billion Commitment From State Bank of India	MT

Press Releases

08/05	Sun Pharma To Acquire Organon	AQ
28/04	India’s Sun Pharma agrees all cash takeover of Organon	AQ
02/03	Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami	AQ
16/01	Sun Pharma Announces the Availability of UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma	AQ
02/01	Sun Pharma Launches ILUMYA® In India	AQ
01/12	Sun Pharma introduces its global innovative drug, Ilumya in India for treatment of moderate-to-severe Plaque Psoriasis	AQ
14/25/14	Delhi HC Rejects CBDT's Endeavor Of Prescribing Limitation Through A Circular In The Absence Of Statutory Backing	AQ
16/25/16	Sun Pharma appoints Kirti Ganorkar as the Managing Director, Dilip Shanghvi to continue as the Executive Chairman of the Board	AQ
12/25/12	Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.	AQ
25/25/25	Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage	AQ
25/24/25	Healthcare \| July And August 2024 - Case Laws	AQ
28/24/28	Sun Pharma Presents LEQSELVI Data Highlighting Clinical Efficacy and Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference	AQ
02/24/02	Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for commercializing the specialty product FIBROMUN	AQ
09/24/09	Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain	AQ
17/24/17	Sun Pharma - Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial Demonstrates Durability of Pain Relief After a Single Injection of MM-II in Patients with Painful Knee Osteoarthritis	AQ
23/24/23	Taro Shareholders Approve Merger with Sun Pharma	AQ
27/23/27	Sun Pharma Canada Launches (PR)WINLEVI® (clascoterone cream 1% w/w), a Novel Topical Treatment for Acne	AQ
14/23/14	Pharmazz Inc. and Sun Pharma enter into licensing agreement for introducing Tyvalzi in India	AQ
26/23/26	Sun Pharma Announces Health Canada Approval of (PR)ABSORICA LD® (isotretinoin capsules) for Treatment of Severe Nodular Acne	AQ
31/23/31	Sun Pharma Announces China NMPA Approval for ILUMETRI for Treatment of Adults with Moderate-To-Severe Plaque Psoriasis	AQ
31/23/31	Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY in Europe, Australia and New Zealand	AQ
21/22/21	Sun Pharmaceutical Industries Limited - SEZABY approved by US FDA for the treatment of neonatal seizures	AQ
23/22/23	Sun Pharmaceutical Industries : Litigations/Disputes/Regulatory actions	PU
28/22/28	Sun Pharma launches PrCEQUA, the first dry eye treatment with nanomicellar technology, in Canada	AQ
25/22/25	Sun Pharmaceutical Industries : Dividend Updates	PU